Metastatic breast cancer (MBC) remains an incurable disease, despite major advances in the treatment in the past 1012 years. Data on real life overall survival in a non-selected group containing all metastatic breast cancer patients are hard to find in the literature, as is the correlation of ...
A new study led by Susan G. Komen Scholars indicates that patients diagnosed with de novo stage 4 breast cancer—also called metastatic breast cancer—had improved survival rates and decreased mortality rates when those patients had access to care. De novo means the breast cancer was stage 4 at...
According to international guidelines, endocrine therapy (ET) is the preferred option for hormone receptor-positive (HR+) HER2-negative (HER2−) metastatic breast cancer. In spite of clear recommendations, these are not strictly followed in daily practice. The objectives of this study were to inv...
Estimating Typical, Best-Case, and Worst-Case Scenarios for Patients Starting First-line Chemotherapy for Metastatic Breast Cancer: A Systematic Review of Recent Randomized Trials Kiely BE, Soon YY, Tattersall MH, Stockler MR J Clin Oncol. 2011;29:456-463 Study Summary In a meta-analysis from...
The median survival of women with metastatic breast cancer (MBC) is 18–24 months, and fewer than 5% are alive and disease free at 5 years. We report toxicity and survival in a cohort of MBC patients receiving high-dose chemotherapy (HDC) with autologous hematopoietic SCT (AHSCT) in Italy...
Multiple interactions between obesity-linked inflammation, adipose tissue activation or diet-induced metabolic changes and cancer risk or response to treatment have been described [[13], [14], [15]]. In patients with metastatic breast cancer (MBC), limited data are available regarding the impact ...
The death rate for women with metastatic breast cancer is linked to the number of chronic health conditions they have, according to a study by the University of Michigan in partnership with the Kaiser Permanente Southern California Department of Research
Real-world 1-year survival analysis of patients with metastatic breast cancer with liver or lung metastasis treated with eribulin, gemcitabine or capecitabine - ScienceDirectBackground Pooled analyses from 2 phase III trials of patients (pts) with metastatic breast cancer (mBC) treated with eribulin...
Johnson MM et al (2011) High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized... Jun,Ren,Lijun,... - 《Clinical & Translational Oncology》 被引量: 97发表: 2013年 High-dose chemotherapy consolidation with autologous ste...
Researchers have developed a fairly comprehensive picture of the anticipated storyline for each particular type of cancer.